DEA sent a letter to all DEA registrants informing them that the DATA-Waiver Program was eliminated after the Consolidated Appropriations Act of 2023 was signed on December 29, 2022. Since then, the “DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.” Furthermore, “all prescriptions for buprenorphine will only require a standard DEA registration number,” and prescribers no longer have any limits on the number of patients they may treat for opioid use disorder with buprenorphine.